hFCRN(2)

The endogenous mouse Fcgrt gene was replaced by human FCGRT gene.While hFCRN(Stock No.NM-HU-00109) and hFCRN(3)(Stock No.NM-HU-2000032）mice function similarly to hFCRN(2) mice,for more detailed information please contact our technical advisor.

Fig1. Validation of hFCGRT and mFCGRT expression in humanized Fcgrt mice by WB. These results showed that hFCGRT can be expressed in the liver and kidney of humanized Fcgrt homozygous and heterozygous mice，while mFCGRT can not be expressed in the humanized Fcgrt homozygous mice.

Fig2. Detection of FCRN expression in hFCRN(2) mice by WB. The spleen, large intestine and small intestine tissue lysates were collected from 12-week-old female wild-type C57BL/6 mice and 12-week-old female homozygous hFCRN(2) mice, and then analyzed by western blot with anti-FCRN antibody. FCRN was detectable in spleen, large intestine from both WT C57BL/6 and HO hFCRN(2) mice. 

Abbr. HO, homozygous; WT, wild type.

Fig.3 Detection of mIgG1 expression in serum by ELISA (n=3). 

Abbr. HO, homozygous;  WT, wild type.

Fig.4 Blood routine test of hFCRN(2) mice (n=5 males and 5 females). 

Fig.5 Blood Biochemistry of hFCRN(2) mice (n=5 males and 5 females). 

Fig.6 Frequency of leukocyte and myeloid subpopulations in the blood by flow cytometry. hFCRN(2) knockin mice showed a normal immune phenotype in blood. Blood was collected from WT C57BL/6 mice and HO hFCRN(2) mice (8-week-old, n=6). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the blood. Bar indicated expressed as mean ± SEM.

Abbr.  HO, homozygous; WT, wild type.

Fig.7 Frequency of leukocyte and myeloid subpopulations in the spleen by flow cytometry. hFCRN(2) knockin mice showed a normal immune phenotype in spleen. Spleen was collected from WT C57BL/6 mice and HO hFCRN(2) mice (8-week-old, n=6). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the spleen. Bar indicated expressed as mean ± SEM.

Abbr.  HO, homozygous; WT, wild type.

Fig.8 Frequency of leukocyte and myeloid subpopulations in the bone marrow by flow cytometry. hFCRN(2) knockin mice showed a normal immune phenotype in bone marrow. Bone marrow was collected from WT C57BL/6 mice and HO hFCRN(2) mice (8-week-old, n=6). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the bone marrow. Bar indicated expressed as mean ± SEM.

Abbr.  HO, homozygous; WT, wild type.

Fig.9 Blood concentration curves of Keytruda in C57BL/6 and hFcRn KI mice. (n=3/time point/group)

Fig.10 Blood concentration curves of Cyramza(A) and Keytruda(B) in C57BL/6, hFCRN(2) and Fcgrt-KO mice.(n=3/time point/group)

Fig.11 In vivo PK profiles of TAA scfv-anti HSA VHH in hALB/hFCRN(2) mice(NM-HU-200278) (female, 10-12weeks, n=3 mice/timepoint), which were generated by crossing hFCRN(2)(NM-HU-190070) with hALB(NM-HU-200003). (In cooperation with the third party).

Fig.12 Blood concentration curves of test articles in C57BL/6 and hALB/hFCRN(2) mice(NM-HU-200278), which were generated by crossing hFCRN(2)(NM-HU-190070) with hALB(NM-HU-200003).(In cooperation with the third party)

Fig.13 Pharmacokinetic analysis of IBI112 in HO hFCRN(2) mice. (A) Body weight. (B) Pharmacokinetic analysis parameters. On Day 0, WT C57BL/6 and HO hFCRN(2) mice were intravenously injected via the tail vein with IBI112 (hIgG1 Fc) and the YTE-modified IBI112 antibody (5 mg/kg), respectively. Blood was drawn at the indicated times, and serum was obtained for pharmacokinetic analysis (n=3 females, 8-10 weeks old). The results showed that, although a prolonged half-life of the YTE-modified IBI112 antibody in HO hFCRN(2) mice compared to WT C57BL/6 mice, the difference was not statistically significant due to large within-group variation. Data are shown as mean ± SEM.